"Mind in Motion": Multimodal Imaging of Brain Activity to Investigate Walking and Mobility Decline in Older Adults

NCT ID: NCT03737760

Last Updated: 2025-07-17

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

279 participants

Study Classification

OBSERVATIONAL

Study Start Date

2019-04-19

Study Completion Date

2025-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The objective of this study is to determine the central neural control of mobility in older adults by acquiring data with multiple modalities of neuroimaging (EEG, fNIRS, MRI) and associating these data with a comprehensive set of diverse mobility outcomes (clinic-based walking, complex walking and community mobility measures).

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study is a longitudinal, prospective cohort study with a follow-up period of 1.2 - 3.5 years, dependent on when the participant enrolls. Participants will be assessed at baseline, and then every six months for 3.5 years or until the study ends, whichever comes first.

The investigators plan to enroll 200 community-dwelling men and women age 70+ years.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Effect of Age-related Changes in the Brain on Walking Ability

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Older Adults

Community-dwelling men and women age 70+ years

No interventions assigned to this group

Younger Adults

Healthy young adults, age 20-40 years for baseline assessments only

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Community dwelling men and women 65+ years old, or 60+ for individuals who belong to underrepresented racial or ethnic groups;
* Short Physical Performance Battery (SPPB) \<10 (45% of the sample will have an SPPB \< 8) for moderate to low functioning older adults; SPPB\>=10 for high functioning older adults
* Able to complete the 400 m walk test within 15 minutes without sitting or the help of another person and without a walker, a cane is allowed
* Willingness to undergo all testing procedures
* English speaking
* Willingness to be enrolled for 1.25 to 3.5 years, depending on enrollment date.


* Healthy men and women aged 20-40 years old
* Willingness to undergo all testing procedures
* English speaking

Exclusion Criteria

* Significant medical event requiring hospitalization in the past 6 months that has the potential to contaminate data being collected (fracture, hospitalization etc.);
* Severe visual impairment or corrected visual acuity less than 20/40, which would preclude completion of the assessments;
* Not meeting MRI eligibility (e.g. metal implants, pacemaker, etc.)
* Clinically diagnosed vestibular dysfunction;
* Unwilling or unable to do an over-ground version of the uneven terrain task without assistive device;
* Develops chest pain or severe shortness of breath during physical stress;
* Stroke or other brain injury within the past three years;
* Current presence of motor deficits caused by a stroke or other brain injury;
* Diagnosis of dementia or taking cholinesterase inhibitors (Aricept, Exelon, Razadyne, Namenda, or Namzaric);
* Any major ADL disability (unable to feed, dress, bath, use the toilet, or transfer);
* Report of severe lower extremity pain that significantly limits mobility;
* Diagnosis or treatment for rheumatoid arthritis;
* Lives in a nursing home; persons living in assisted or independent housing will not be excluded;
* Receiving physical therapy for gait, balance, or other lower extremity training;
* Known neuromuscular disorder or overt neurological disease (e.g. Multiple Sclerosis, Rhabdomyolysis, Myasthenia Gravis, Ataxia, Apraxia, post-polio syndrome, mitochondrial myopathy, Parkinson's Disease, ALS etc.)
* Unable to communicate because of severe hearing loss or speech disorder;
* Planned surgical procedure or hospitalization in the next 12 months (e.g., joint replacement, CABG);
* Severe pulmonary disease, requiring the use of supplemental oxygen;
* Terminal illness, as determined by a physician;
* Severe cardiac disease, including NYHA Class III or IV congestive heart failure, clinically significant aortic stenosis, recent history of cardiac arrest, use of a cardiac defibrillator, or uncontrolled angina;
* Is planning to move out of the area in next year or leave the area for \>6 mos during follow-up;
* Other significant conditions that would impact safety and/or compliance to the protocol (e.g. renal failure on hemodialysis, psychiatric disorder-bipolar, schizophrenia, excessive alcohol intake etc.);

-Actively enrolled in an intervention study
* Use of walker or wheel chair;
* Artificial hair covering the scalp such as a wig or toupee
* Failure to provide informed consent;
* Transaminases \>twice upper limit of normal;
* Hemoglobin \<10 g/dL;
* Investigator discretion based on safety or compliance concerns

* Abnormalities in blood chemistry parameters as defined above;
* Severe hypertension, e.g., SBP \> 200, DBP \> 110 mmHg;
* Uncontrolled diabetes or hyperglycemia (fasting blood glucose \> 126 mg/dl or hemoglobin A1C \> 6.5%)
* Other temporary events that would influence participation (e.g. episodic health event, sick spouse, bereavement, or recent move);
* Other conditions identified with medical history at enrollment that places the participant at risk for participation.
Minimum Eligible Age

20 Years

Maximum Eligible Age

110 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

National Institute on Aging (NIA)

NIH

Sponsor Role collaborator

University of Florida

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

David Clark, ScD

Role: PRINCIPAL_INVESTIGATOR

University of Florida

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University of Florida

Gainesville, Florida, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

1U01AG061389-01

Identifier Type: NIH

Identifier Source: secondary_id

View Link

OCR19439

Identifier Type: OTHER

Identifier Source: secondary_id

P30AG059297

Identifier Type: NIH

Identifier Source: secondary_id

View Link

IRB201900001

Identifier Type: OTHER

Identifier Source: secondary_id

IRB202201585

Identifier Type: OTHER

Identifier Source: secondary_id

IRB201802227-N

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Brain and Mindfulness
NCT03117478 COMPLETED NA
Studying Motor Neuron Tests
NCT01517087 COMPLETED
Reliability of the Human Brain Connectome
NCT02193425 COMPLETED EARLY_PHASE1